Department of Gastroenterology, Hospital Clínic, CIBERehd, IDIBAPS, University of Barcelona, Villarroel 170, 08036, Barcelona, Catalonia, Spain.
Br J Cancer. 2011 Sep 6;105(6):870-5. doi: 10.1038/bjc.2011.296. Epub 2011 Aug 2.
Colorectal cancer (CRC) is the second cause of cancer-related death in the Western world. Much of the CRC genetic risk remains unidentified and may be attributable to a large number of common, low-penetrance genetic variants. Genetic linkage studies in CRC families have reported additional association with regions 9q22-31, 3q21-24, 7q31, 11q, 14q and 22q. There are several plausible candidate genes for CRC susceptibility within the aforementioned linkage regions including PTCH1, XPA and TGFBR1 in 9q22-31, and EPHB1 and MRAS in 3q21-q24.
CRC cases and matched controls were from EPICOLON, a prospective, multicentre, nationwide Spanish initiative, composed of two independent phases. Phase 1 corresponded to 515 CRC cases and 515 controls, whereas phase 2 consisted of 901 CRC cases and 909 controls. Genotyping was performed for 172 single-nucleotide polymorphisms (SNPs) in 84 genes located within regions 9q22-31 and 3q21-q24.
None of the 172 SNPs analysed in our study could be formally associated with CRC risk. However, rs1444601 (TOPBP1) and rs13088006 (CDV3) in region 3q22 showed interesting results and may have an effect on CRC risk.
TOPBP1 and CDV3 genetic variants on region 3q22 may modulate CRC risk. Further validation and meta-analysis should be undertaken in larger CRC cohorts.
结直肠癌(CRC)是西方世界第二大癌症相关死亡原因。大多数 CRC 遗传风险仍然未知,可能归因于大量常见的、低外显率的遗传变异。CRC 家族的遗传连锁研究报告了与 9q22-31、3q21-24、7q31、11q、14q 和 22q 区域的额外关联。在上述连锁区域内有几个结直肠癌易感性的合理候选基因,包括 9q22-31 中的 PTCH1、XPA 和 TGFBR1,以及 3q21-q24 中的 EPHB1 和 MRAS。
CRC 病例和匹配对照来自 EPICOLON,这是一项前瞻性、多中心、全国性的西班牙倡议,由两个独立的阶段组成。第一阶段包括 515 例 CRC 病例和 515 例对照,第二阶段包括 901 例 CRC 病例和 909 例对照。对位于 9q22-31 和 3q21-q24 区域的 84 个基因内的 172 个单核苷酸多态性(SNP)进行了基因分型。
在我们的研究中分析的 172 个 SNP 中没有一个可以正式与 CRC 风险相关。然而,位于 3q22 的 rs1444601(TOPBP1)和 rs13088006(CDV3)显示出有趣的结果,可能对 CRC 风险有影响。
位于 3q22 的 TOPBP1 和 CDV3 遗传变异可能调节 CRC 风险。应该在更大的 CRC 队列中进行进一步的验证和荟萃分析。